Pharmacy Compounding Advisory Committee Votes Mostly In Unison
In first meeting after multi-year absence, FDA’s Pharmacy Compounding Advisory Committee takes 33 votes on do-not-compound and bulk substances lists.
You may also be interested in...
ANDAs mistakenly still are cataloged as approved even though they have been withdrawn from marketing.
After years where many more applications received priority assessments than standard assessments, in FY 2022 the difference narrowed.
Nonclinical testing questions should be answered in a pre-IND meeting, rather than the new Type D session. A US FDA Center for Biologics Evaluation and Research official also indicated support for alternatives to animal testing when possible.